
Last update at 2026-03-11T14:58:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Teleflex (NYSE:TFX) Is Paying Out A Dividend Of $0.34
Thu 15 May 25, 11:10 AMTFX Q1 Earnings Call: Guidance Cut and Strategic Shifts Dominate Amid Tariff Headwinds
Wed 14 May 25, 09:57 PM3 Reasons to Avoid TFX and 1 Stock to Buy Instead
Mon 12 May 25, 04:02 AMSome May Be Optimistic About Teleflex's (NYSE:TFX) Earnings
Thu 08 May 25, 10:29 AMTeleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up
Mon 05 May 25, 11:24 AMResults: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Sun 04 May 25, 01:51 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 445.92M | 559.47M | 357.73M | 339.90M | 219.63M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M |
| Selling general administrative | 863.75M | 860.09M | 743.57M | 934.37M | 878.69M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1531.09M | 1549.60M | 1324.87M | 1491.61M | 1384.44M |
| Reconciled depreciation | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M |
| Ebit | 499.73M | 628.10M | 423.07M | 427.25M | 400.49M |
| Ebitda | 745.02M | 797.37M | 689.97M | 659.18M | 610.47M |
| Depreciation and amortization | 245.30M | 169.27M | 266.90M | 231.93M | 209.98M |
| Non operating income net other | 0.46M | -11.65800M | 1.16M | -7.08100M | 0.94M |
| Operating income | 499.73M | 628.10M | 423.07M | 427.25M | 321.70M |
| Other operating expenses | 2277.52M | 2250.89M | 2075.60M | 2151.98M | 2048.84M |
| Interest expense | 54.26M | 56.97M | 66.49M | 80.27M | 103.02M |
| Tax provision | 83.00M | 74.35M | 21.93M | -122.07800M | 23.20M |
| Interest income | 53.35M | 55.64M | 1.16M | 1.74M | 0.94M |
| Net interest income | -53.35200M | -55.64100M | -65.33600M | -78.52900M | -102.07600M |
| Extraordinary items | 0.22M | 0.26M | -0.47700M | -0.51500M | 4.37M |
| Non recurring | 20.30M | 21.74M | 38.49M | 22.20M | 79.23M |
| Other items | - | - | - | - | - |
| Income tax expense | 83.00M | 74.35M | 21.93M | -122.07800M | 23.20M |
| Total revenue | 2791.04M | 2809.56M | 2537.16M | 2595.36M | 2448.38M |
| Total operating expenses | 1017.57M | 990.93M | 863.32M | 1048.23M | 984.90M |
| Cost of revenue | 1259.95M | 1259.96M | 1212.28M | 1103.75M | 1063.94M |
| Total other income expense net | -53.80600M | -68.62700M | -65.33600M | -87.35100M | -77.84200M |
| Discontinued operations | 0.22M | 0.26M | -0.47700M | -0.51500M | 4.37M |
| Net income from continuing ops | 362.92M | 485.12M | 335.80M | 461.98M | 196.43M |
| Net income applicable to common shares | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 6928.06M | 6871.72M | 7152.56M | 6309.82M | 6277.99M |
| Intangible assets | 2306.16M | 2289.07M | 2519.75M | 2156.28M | 2325.05M |
| Earning assets | - | - | - | - | - |
| Other current assets | 125.08M | 117.28M | 115.44M | 97.94M | 72.48M |
| Total liab | 2906.09M | 3116.97M | 3816.10M | 3330.50M | 3738.01M |
| Total stockholder equity | 4021.97M | 3754.75M | 3336.46M | 2979.32M | 2539.98M |
| Deferred long term liab | - | - | - | 439.56M | 608.22M |
| Other current liab | 367.19M | 55.63M | 53.87M | 181.49M | 383.18M |
| Common stock | 47.96M | 47.93M | 47.81M | 47.54M | 47.25M |
| Capital stock | 47.96M | 47.93M | 47.81M | 47.54M | 47.25M |
| Retained earnings | 3817.30M | 3517.95M | 3096.23M | 2824.92M | 2427.60M |
| Other liab | 580.14M | 580.72M | 812.09M | 807.13M | 1075.56M |
| Good will | 2536.73M | 2504.20M | 2585.97M | 2245.30M | 2246.58M |
| Other assets | 95.77M | 75.92M | 150.51M | 44.95M | 37.42M |
| Cash | 292.03M | 445.08M | 375.88M | 301.08M | 357.16M |
| Cash and equivalents | 292.03M | 445.08M | 375.88M | 301.08M | 357.16M |
| Total current liabilities | 581.49M | 680.12M | 540.03M | 563.05M | 582.46M |
| Current deferred revenue | - | 396.25M | 283.14M | 228.65M | 5.94M |
| Net debt | 1539.93M | 1521.05M | 2188.61M | 1709.23M | 1801.66M |
| Short term debt | 87.50M | 110.00M | 100.50M | 50.00M | 86.62M |
| Short long term debt | 87.50M | 110.00M | 100.50M | 50.00M | 86.62M |
| Short long term debt total | 1831.96M | 1966.13M | 2564.49M | 2010.32M | 2158.82M |
| Other stockholder equity | 560.23M | 535.82M | 489.71M | 451.26M | 406.22M |
| Property plant equipment | 578.42M | 573.41M | 473.91M | 430.72M | 432.77M |
| Total current assets | 1410.98M | 1429.12M | 1422.42M | 1306.33M | 1236.17M |
| Long term investments | - | - | - | 13.07M | - |
| Net tangible assets | -820.92700M | -1038.52100M | -1769.25500M | -1422.27000M | -2031.65300M |
| Short term investments | - | - | - | - | - |
| Net receivables | 408.83M | 383.57M | 395.07M | 418.67M | 366.29M |
| Long term debt | 1624.02M | 1740.10M | 2377.89M | 1858.94M | 2072.20M |
| Inventory | 578.51M | 477.64M | 513.20M | 476.56M | 427.78M |
| Accounts payable | 126.81M | 118.24M | 102.52M | 102.92M | 106.71M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -403.52200M | -346.95900M | -297.29800M | -344.39200M | -341.08500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 47.96M | 47.93M | 47.81M | 47.54M | 47.25M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 3817.30M | 3517.95M | 3096.23M | 2824.92M | 2427.60M |
| Treasury stock | -154.88900M | -157.26600M | -162.59000M | -165.72000M | -168.54500M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 89.37M | 69.10M | 41.80M | 52.45M | 34.98M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5517.08M | 5442.60M | 5730.13M | 5003.49M | 5041.82M |
| Capital lease obligations | 120.44M | 116.03M | 86.10M | 101.37M | - |
| Long term debt total | 1624.02M | 1740.10M | 2377.89M | 1858.94M | 2072.20M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -257.94100M | -18.41800M | 19.34M | 18.33M | 1.55M |
| Change to liabilities | -104.23900M | 94.02M | -12.64800M | 29.49M | 26.66M |
| Total cashflows from investing activities | -257.94100M | 156.74M | -837.78300M | -73.48100M | -196.39400M |
| Net borrowings | -145.45000M | -634.50000M | 566.56M | 275.00M | 35.00M |
| Total cash from financing activities | -217.50600M | -715.82200M | 455.16M | -418.83600M | -206.43300M |
| Change to operating activities | 13.42M | -28.41000M | -4.32300M | -31.02300M | -10.35100M |
| Net income | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M |
| Change in cash | -153.05000M | 69.20M | 74.80M | -56.07800M | 23.60M |
| Begin period cash flow | 445.08M | 375.88M | 301.08M | 357.16M | 333.56M |
| End period cash flow | 292.03M | 445.08M | 375.88M | 301.08M | 357.16M |
| Total cash from operating activities | 342.14M | 651.42M | 436.41M | 439.52M | 437.38M |
| Issuance of capital stock | 0.00000M | 11.10M | - | - | - |
| Depreciation | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M |
| Other cashflows from investing activities | -178.75100M | 228.35M | -766.43000M | 14.35M | 3.88M |
| Dividends paid | -63.78900M | -63.64800M | -63.22100M | -62.82800M | 62.16M |
| Change to inventory | -110.68600M | -11.13800M | -5.49700M | -53.17000M | -37.19800M |
| Change to account receivables | -38.45900M | -0.60000M | 44.75M | -59.79300M | -23.41200M |
| Sale purchase of stock | -4.30800M | 412.45M | 18.99M | 21.21M | 22.66M |
| Other cashflows from financing activities | 730.78M | -41.22200M | 1457.19M | 172.49M | -15.76800M |
| Change to netincome | -6.15700M | -203.15500M | -74.78600M | -93.64500M | 14.57M |
| Capital expenditures | 79.19M | 71.62M | 90.69M | 102.69M | 80.80M |
| Change receivables | -38.45900M | -0.60000M | 44.75M | -59.79300M | -23.41200M |
| Cash flows other operating | 3.90M | -115.80400M | -82.41700M | -63.19200M | 41.24M |
| Exchange rate changes | - | - | - | - | -10.94800M |
| Cash and cash equivalents changes | -134.11000M | 93.05M | 54.52M | -55.24900M | 23.60M |
| Change in working capital | -239.96400M | 127.34M | 22.28M | -114.49600M | -44.29700M |
| Stock based compensation | 27.22M | 22.94M | 20.74M | 26.94M | 22.44M |
| Other non cash items | -25.84000M | -111.36000M | -136.51400M | 20.15M | 54.55M |
| Free cash flow | 262.95M | 579.80M | 345.71M | 336.83M | 356.58M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TFX Teleflex Incorporated |
0.15 0.13% | 111.99 | 29.27 | 17.27 | 4.00 | 2.70 | 4.36 | 16.14 |
| ISRG Intuitive Surgical Inc |
-0.54 0.11% | 485.31 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-1.02 0.83% | 121.48 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 243.04 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-0.39 0.24% | 163.49 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
550 East Swedesford Road, Wayne, PA, United States, 19087-1603
| Name | Title | Year Born |
|---|---|---|
| Mr. Liam J. Kelly | Chairman, Pres & CEO | 1967 |
| Mr. Thomas E. Powell | Exec. VP & CFO | 1962 |
| Mr. Cameron P. Hicks | Corp. VP & Chief HR Officer | 1965 |
| Mr. Jay White | Corp. VP & Pres of Global Commercial | 1974 |
| Mr. James P. Winters | Corp. VP, Manufacturing and Supply Chain | NA |
| Mr. John R. Deren | Corp. VP & Chief Accounting Officer | NA |
| Mr. John Hsu C.F.A. | VP of Investor Relations | NA |
| Mr. Daniel V. Logue | Corp. VP, Gen. Counsel & Sec. | 1974 |
| Mr. Howard Cyr | Corp. VP & Chief Compliance Officer | NA |
| Mr. Matt Tomkin | VP of Corp. Devel. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.